A5034413859- Cancer Risks and Factors
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Metabolism, Diabetes, and Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Breast Cancer Therapies
- Vitamin D Research Studies
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
- Chemotherapy-induced cardiotoxicity and mitigation
- Economic and Financial Impacts of Cancer
- Breast Lesions and Carcinomas
- Biomedical Ethics and Regulation
- Cancer-related Molecular Pathways
- Ethics in Clinical Research
- Chemotherapy-related skin toxicity
- Cardiac Imaging and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Estrogen and related hormone effects
- Cancer-related cognitive impairment studies
- Monoclonal and Polyclonal Antibodies Research
- Global Cancer Incidence and Screening
- Takotsubo Cardiomyopathy and Associated Phenomena
- Hair Growth and Disorders
- Cancer Genomics and Diagnostics
Université Laval
2016-2025
Centre hospitalier universitaire de Québec
2014-2025
Hôpital du Saint-Sacrement
2013-2025
Université du Québec à Chicoutimi
2014-2024
Indiana University Bloomington
2024
Centre hospitalier de l'Université Laval
2018-2023
Hôpital de l'Enfant-Jésus
2020
BC Cancer Agency
2007-2019
Juravinski Cancer Centre
2011-2019
Ontario Institute for Cancer Research
2019
<h3>Importance</h3> Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. <h3>Objective</h3> To determine whether the administration of adjuvant metformin (vs placebo) patients without diabetes improves outcomes. <h3>Design, Setting, Participants</h3> MA.32, phase 3 randomized, placebo-controlled, double-blind trial, conducted Canada, Switzerland, US, UK,...
The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (BC) is unknown.The MA.31 trial compared a combination anti-HER2 therapy (lapatinib or trastuzumab) and taxane for 24 weeks, followed by same monotherapy until progression. Stratification was prior (neo)adjuvant therapy, taxane, planned liver metastases. primary end point intention-to-treat (ITT) progression-free...
Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC Clinical Trials Group (NCIC CTG) MA.32 investigates effects of metformin vs placebo on invasive disease-free survival and other outcomes in early cancer. Maintaining blinding investigators to outcomes, we conducted a planned, Data Safety Monitoring Committee–approved, analysis the effect weight at six months, including...
Although antineoplastic agents are critical in the treatment of cancer, they can potentially cause hypersensitivity reactions that have serious consequences. When such a reaction occurs, clinicians either continue treatment, at risk causing severe or fatal anaphylactic reaction, stop although it might be only one available. The objective present work was to evaluate effectiveness methods used prevent and treat platinum- taxane-based chemotherapy develop evidence-based recommendations.The...
Abstract Background Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity restoring inhibition of AKT by everolimus. This study evaluated the addition xentuzumab everolimus exemestane in patients with advanced breast cancer non-visceral disease. Methods double-blind, randomised, Phase II was undertaken female hormone-receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative disease who had received prior endocrine...
Adjuvant endocrine therapy (AET) is prescribed for 5-10 years to women with hormone-sensitive breast cancer prevent recurrence. However, a significant proportion of do not adhere AET. We developed SOIE, one-year program designed enhance the AET experience and adherence. SOIE was pilot-tested in mixed-methods randomized controlled trial. This report presents healthcare providers (HCPs) SOIE. A descriptive qualitative study using semi-structured interviews thematic analysis conducted 20 7 HCPs...
Febrile neutropenia (FN) is a serious complication of chemotherapy that often leads to hospitalization in cancer patients. It now well-established carefully selected patients can be safely treated on an outpatient basis. The objective this study was assess the number and proportion hospitalized for FN university hospital setting who would have met low-risk criteria FN, whether these experienced favorable outcomes during hospitalization. We conducted retrospective all admitted at three...